---
company: Silexion Therapeutics Corp
ticker: SLXN
form: 8-K
filed: 2026-05-18
accession: 0001178913-26-002761
source: https://www.sec.gov/Archives/edgar/data/2022416/000117891326002761/
---

# Silexion Therapeutics (SLXN) earnings release, May 18, 2026

Silexion Therapeutics Corp (SLXN) · Form 8-K, Item 2.02 · Filed 2026-05-18 · [SEC filing](https://www.sec.gov/Archives/edgar/data/2022416/000117891326002761/)

Silexion Therapeutics Reports First Quarter 2026 Financial Results and

Provides Business Update

Israeli Ministry of Health approved the initiation of Silexion's Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer

Clinical Trial Application subsequently submitted to Germany through the EU Clinical Trials

Information System

Phase 2/3 clinical trial initiation remains on track for the second quarter of 2026

Grand Cayman, Cayman Islands, May 18, 2026 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("

Silexion

" or the "

Company

"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today provided an update on recent business developments following the release of its financial results for the first quarter ended March 31, 2026, which were reported on May 15, 2026.

Recent Milestones & Business Highlights

Ilan Hadar, Chairman and Chief Executive Officer of Silexion, commented: “The first quarter and the period since represented a defining moment in Silexion's evolution. With the Israeli Ministry of Health approval to initiate our Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer, and our subsequent submission of a Clinical Trial Application to Germany under the EU Clinical Trials Regulation, we have advanced SIL204 from a preclinical asset into clinical-stage development across two major regulatory jurisdictions. We remain on track to initiate the Phase 2/3 clinical trial in the second quarter of

2026, with the goal of bringing an RNAi-based approach to patients with KRAS-driven cancers who have limited treatment options today.”

Mirit Horenshtein Hadar, Chief Financial Officer of Silexion, added: “During the first quarter and subsequent to quarter end, we executed a series of capital-raising and corporate actions designed to support our clinical development plan and our continued Nasdaq listing. These included our May 2026 warrant exercise inducement transaction, additional capital raised under our at-the-market facility, and obtaining shareholder approval for a prospective reverse share split. We continue to evaluate financing alternatives as we work to support the advancement of SIL204 into the clinic in the second quarter of 2026.”

Financial Results for the Three Months Ended March 31, 2026

Balance Sheet Highlights

About Silexion Therapeutics

Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product, which showed a positive trend in comparison to the control of chemotherapy alone, and is currently advancing its lead, second-generation, product candidate, SIL204, a small interfering RNA (siRNA), towards clinical trials in Israel and the European Union. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer. For more information please visit: https://silexion.com

Notice Regarding Forward-Looking

Statements:

This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including, for example, statements regarding the development of SIL204; the timing, design, conduct, and initiation of the planned Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer (including the expected commencement in the second quarter of 2026, the safety run-in and randomized cohort design, and patient enrollment); the timing, content, outcome, and review of regulatory submissions and interactions with regulatory authorities in Israel, Germany, the European Union, and other jurisdictions, including the expected scientific assessment under the EU Clinical Trials Regulation with Germany as Reporting Member State; the conduct of clinical trial activities in Germany; the Company's anticipated future financing activities; the Company’s planned reverse share split and the timing of its effectiveness; the Company's restoration and future maintenance of compliance with the continued listing requirements of the Nasdaq Capital Market, including the shareholders' equity requirement; the potential therapeutic benefits, mutation coverage, and clinical utility of SIL204 across multiple cancer types; Silexion's business strategy and development plans; and Silexion's future capital requirements and ability to raise additional capital, are forward-looking statements. These forward-looking statements are generally identified by terminology such as “may”, “should”, “could”, “might”, “plan”, “possible”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “prospective”,

“potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) whether Silexion will succeed at initiating and conducting clinical trials, including the Phase 2/3 trial of... (truncated)ted; (iii) the impact of the regulatory environment and compliance complexities; (iv) whether Silexion can establish future partnerships or other relationships with third parties; (v) Silexion's future capital requirements and sources and uses of cash, including its ability to obtain additional capital;

(vi) whether Silexion can maintain its Nasdaq listing, including its ability to continue to satisfy the Nasdaq shareholders' equity and minimum bid price requirements; and (vii) other risks and uncertainties set forth in the documents filed by the

Company with the SEC, including the Company's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 17, 2026, and the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 15, 2026. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made.

Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.

Company Contact:

Silexion Therapeutics Corp

Ms. Mirit Horenshtein Hadar, CFO mirit@silexion.com

Investor Relations

Arx Investor Relations

North American Equities Desk silexion@arxhq.com

SILEXION THERAPEUTICS

## Financial statements

### Income Statement (Three months ended March 31, — (U.S. dollars in thousands, except share and per share data))

| | Three months ended March 31, – 2026 | Three months ended March 31, – 2025 |
|---|---:|---:|
| OPERATING EXPENSES: | Research and development (including $130 and $0 from related parties for the three-month periods ended March 31, 2026 and 2025, respectively) | 1,370 | 590 |
| OPERATING EXPENSES: | General and administrative (including $215 and $21 from related parties for the three-month periods ended March 31, 2026 and 2025, respectively) | 1,379 | 1,060 |
| OPERATING EXPENSES: | TOTAL OPERATING EXPENSES | 2,749 | 1,650 |
| OPERATING EXPENSES: | OPERATING LOSS | 2,749 | 1,650 |
| OPERATING EXPENSES: | Financial expense (income), net (including $(15) and $32 from related parties for the three-month periods ended March 31, 2026 and 2025, respectively) | -16 | 85 |
| OPERATING EXPENSES: | LOSS BEFORE INCOME TAX | 2,733 | 1,735 |
| OPERATING EXPENSES: | NET LOSS | 2,733 | 1,735 |
| OPERATING EXPENSES: | LOSS PER SHARE, BASIC AND DILUTED | 0.85 | 3.84 |
| OPERATING EXPENSES: | WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE | 3,230,378 | 451,990 |

### Balance Sheet (December 31, — (U.S. dollars in thousands, except share data))

| | March 31, – 2026 | December 31, – 2025 |
|---|---:|---:|
| CURRENT ASSETS: | Cash and cash equivalents | 2,413 | 5,991 |
| CURRENT ASSETS: | Restricted cash | 27 | 27 |
| CURRENT ASSETS: | Prepaid expenses | 1,529 | 570 |
| CURRENT ASSETS: | Other current assets | 96 | 49 |
| CURRENT ASSETS: | TOTAL CURRENT ASSETS | 4,065 | 6,637 |
| NON-CURRENT ASSETS: | Restricted cash | 58 | 57 |
| NON-CURRENT ASSETS: | Long-term deposit and other non-current assets | 76 | 84 |
| NON-CURRENT ASSETS: | Property and equipment, net | 23 | 25 |
| NON-CURRENT ASSETS: | Operating lease right-of-use asset | 380 | 412 |
| NON-CURRENT ASSETS: | TOTAL NON-CURRENT ASSETS | 537 | 578 |
| NON-CURRENT ASSETS: | TOTAL ASSETS | 4,602 | 7,215 |

### Balance Sheet (December 31, — (U.S. dollars in thousands, except share data))

| | March 31, – 2026 | December 31, – 2025 |
|---|---:|---:|
| CURRENT LIABILITIES: | Trade payables | 912 | 787 |
| CURRENT LIABILITIES: | Current maturities of operating lease liability | 185 | 182 |
| CURRENT LIABILITIES: | Employee related obligations | 560 | 879 |
| CURRENT LIABILITIES: | Other account payable | 850 | 910 |
| CURRENT LIABILITIES: | Related Party Promissory Note | 1,553 |  |
| CURRENT LIABILITIES: | TOTAL CURRENT LIABILITIES | 4,060 | 2,758 |
| NON-CURRENT LIABILITIES: | Long-term operating lease liability | 251 | 286 |
| NON-CURRENT LIABILITIES: | Related Party Promissory Note |  | 1,568 |
| NON-CURRENT LIABILITIES: | TOTAL NON-CURRENT LIABILITIES | 251 | 1,854 |
| NON-CURRENT LIABILITIES: | TOTAL LIABILITIES | 4,311 | 4,612 |
| SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY): | Ordinary shares ($0.0135 par value per share, 9,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 3,394,865 and 3,126,651 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively) | 46 | 42 |
| SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY): | Additional paid-in capital | 58,144 | 57,727 |
| SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY): | Accumulated deficit | -57,899 | -55,166 |
| SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY): | TOTAL SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) | 291 | 2,603 |
| SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY): | TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) | 4,602 | 7,215 |
